Author Correction: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness

被引：0
|
作者：
Ming-Jenn Chen
De-Wei Wu
Yao-Chen Wang
Chi-Yi Chen
Huei Lee
机构：
[1] Chi Mei Medical Center,Department of Surgery
[2] Taipei Medical University,Graduate Institute of Cancer Biology and Drug Discovery
[3] Chung Shan Medical University,School of Medicine
[4] Chung Shan Medical University Hospital,Division of Pulmonary Medicine, Department of Internal Medicine
[5] Chung Shan Medical University,Department of Surgery
[6] Chia Nan University of Pharmacy and Science,Department of Sports Management, College of Leisure and Recreation Management
来源：
Scientific Reports | / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
引用
收藏
相关论文
共 50 条
  • [1] PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness
    Chen, Ming-Jenn
    Wu, De-Wei
    Wang, Yao-Chen
    Chen, Chi-Yi
    Lee, Huei
    SCIENTIFIC REPORTS, 2016, 6
  • [2] PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness
    Ming-Jenn Chen
    De-Wei Wu
    Yao-Chen Wang
    Chi-Yi Chen
    Huei Lee
    Scientific Reports, 6
  • [3] Correction: Corrigendum: PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness
    Ming-Jenn Chen
    De-Wei Wu
    Yao-Chen Wang
    Chi-Yi Chen
    Huei Lee
    Scientific Reports, 6
  • [4] PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness (vol 10, 18504, 2020)
    Chen, Ming-Jenn
    Wu, De-Wei
    Wang, Yao-Chen
    Chen, Chi-Yi
    Lee, Huei
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [5] PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness (vol 6, 34933, 2016)
    Chen, Ming-Jenn
    Wu, De-Wei
    Wang, Yao-Chen
    Chen, Chi-Yi
    Lee, Huei
    SCIENTIFIC REPORTS, 2016, 6
  • [6] Overexpression of PAK1 Correlates with Aberrant Expression of EMT Markers and Poor Prognosis in Non-Small Cell Lung Cancer
    Yang, Zhiying
    Wang, Heran
    Xia, Longzheng
    Oyang, Linda
    Zhou, Yujuan
    Zhang, Baihua
    Chen, Xiaoyan
    Luo, Xia
    Liao, Qianjin
    Liang, Jianping
    JOURNAL OF CANCER, 2017, 8 (08): : 1484 - 1491
  • [7] Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis
    Mortazavi, Fariborz
    Lu, Jie
    Phan, Ryan
    Lewis, Michael
    Trinidad, Kenny
    Aljilani, Amir
    Pezeshkpour, Gholamhossein
    Tamanoi, Fuyuhiko
    BMC CANCER, 2015, 15
  • [8] Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis
    Fariborz Mortazavi
    Jie Lu
    Ryan Phan
    Michael Lewis
    Kenny Trinidad
    Amir Aljilani
    Gholamhossein Pezeshkpour
    Fuyuhiko Tamanoi
    BMC Cancer, 15
  • [9] Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
    Ito, Masaoki
    Codony-Servat, Cartes
    Karachaliou, Niki
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 667 - +
  • [10] Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial–mesenchymal transition
    Qiu-di Deng
    Xue-ping Lei
    Yi-hang Zhong
    Min-shan Chen
    Yuan-yu Ke
    Zhan Li
    Jing Chen
    Li-juan Huang
    Yu Zhang
    Lu Liang
    Zhong-xiao Lin
    Qing Liu
    Song-pei Li
    Xi-yong Yu
    Acta Pharmacologica Sinica, 2021, 42 : 1486 - 1497
12345